A Randomized Open-Label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 [remogliflozin etabonate] on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

A Randomized Open-Label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 [remogliflozin etabonate] on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Metformin; Remogliflozin etabonate
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Jun 2009 This study was published as an abstract in the proceedings of the 69th Annual Scientific Sessions of the American Diabetes Association.
    • 17 Apr 2008 Status changed from in progress to completed.
    • 01 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top